Recombinant DNA Technology Market Report: Trends, Forecast and Competitive Analysis
Get it in 2 to 4 weeks by ordering today
The future of the global recombinant DNA technology market looks promising with opportunities in biotechnology & pharmaceutical companies and academic & government research institutes. The global recombinant DNA technology market is expected to grow with a CAGR of 6%-8% from 2020 to 2025. The major drivers for this market are increasing adoption of genetically modified crops & biopesticides and the rising burden of chronic diseases.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global recombinant DNA technology market report, please download the report brochure.
In this market, medical is the largest product type of recombinant DNA technology, whereas pharmaceutical and biotechnology companies is the largest end use. Growth in various segments of the recombinant DNA technology market are given below:
The study includes trends and forecast for the global recombinant DNA technology market by product, component, application, end use, and region as follows:
By Product [Value ($ Million) shipment analysis for 2014 – 2025]:
Lucintel forecasts that medical will remain the largest product segment over the forecast period, as it has facilitated disease treatment by insertion of new genes in place of damaged & diseased genes.
Within this market, pharmaceutical & biotechnology companies will remain the largest end use segment over the forecast period, as the techniques accelerate their drug development capabilities. Moreover, the end products using rDNA techniques in this segment are highly valued and observed to have significant improvement in productivity.
North America will remain the largest region over the forecast period because the presence of effective regulatory bodies to monitor the various ethical and scientific concerns pertaining to the use of technology have driven the regional growth.
Features of the Global Recombinant DNA Technology Market
Q.1 What are some of the most promising potential, high-growth opportunities for the global recombinant DNA technology market by product (medical (therapeutic agent, human protein, and vaccine) and non-medical (biotech crops, specialty chemicals, and others), component (expression system (mammalian, bacteria, yeast, baculovirus / insects, and others) and cloning vector), application (food & agriculture, health & diseases (humans and animals), environment, and others), end-use (biotechnology and pharmaceutical companies, academic & government research institutes, and others), and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global recombinant DNA technology market?
Q.5 What are the business risks and threats to the global recombinant DNA technology market?
Q.6 What are the emerging trends in this recombinant DNA technology market and the reasons behind them?
Q.7 What are some changing demands of customers in this recombinant DNA technology market?
Q.8 What are the new developments in this recombinant DNA technology market? Which companies are leading these developments?
Q.9 Who are the major players in this recombinant DNA technology market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this recombinant DNA technology market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global recombinant DNA technology market?
Report Scope
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling
Market Segments Product (Medical (Therapeutic Agent, Human Protein, and Vaccine) and Non-Medical (Biotech Crops, Specialty Chemicals, and Others), Component (Expression System (Mammalian, Bacteria, Yeast, Baculovirus / Insects, and Others) and Cloning Vector), Application (Food & Agriculture, Health & Diseases (Humans And Animals), Environment, and Others), and End Use (Biotechnology and Pharmaceutical Companies, Academic & Government Research Institutes, and Others)
Regional Scope North America (USA, Mexico, and Canada), Europe (Germany, United Kingdom, Spain, Italy, and France), Asia (China, Japan, and India), and ROW (Brazil)
Customization 10% Customization without Any Additional Cos
The future of the global recombinant DNA technology market looks promising with opportunities in biotechnology & pharmaceutical companies and academic & government research institutes. The global recombinant DNA technology market is expected to grow with a CAGR of 6%-8% from 2020 to 2025. The major drivers for this market are increasing adoption of genetically modified crops & biopesticides and the rising burden of chronic diseases.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global recombinant DNA technology market report, please download the report brochure.
In this market, medical is the largest product type of recombinant DNA technology, whereas pharmaceutical and biotechnology companies is the largest end use. Growth in various segments of the recombinant DNA technology market are given below:
The study includes trends and forecast for the global recombinant DNA technology market by product, component, application, end use, and region as follows:
By Product [Value ($ Million) shipment analysis for 2014 – 2025]:
- Medical
- Therapeutic Agent
- Human Protein
- Vaccine
- Non-Medical
- Biotech Crops
- Specialty Chemicals
- Others
- Expression System
- Mammalian
- Bacteria
- Yeast
- Baculovirus / Insects
- Others
- Cloning Vector
- Food & Agriculture
- Health & Diseases
- Humans
- Animals
- Environment
- Others
- Biotechnology and Pharmaceutical Companies
- Academic & Government Research Institutes
- Others
- North America
- United States
- Canada
- Mexico
- Europe
- United Kingdom
- Germany
- Spain
- Italy
- France
- Asia Pacific
- China
- Japan
- India
- The Rest of the World
- Brazil
Lucintel forecasts that medical will remain the largest product segment over the forecast period, as it has facilitated disease treatment by insertion of new genes in place of damaged & diseased genes.
Within this market, pharmaceutical & biotechnology companies will remain the largest end use segment over the forecast period, as the techniques accelerate their drug development capabilities. Moreover, the end products using rDNA techniques in this segment are highly valued and observed to have significant improvement in productivity.
North America will remain the largest region over the forecast period because the presence of effective regulatory bodies to monitor the various ethical and scientific concerns pertaining to the use of technology have driven the regional growth.
Features of the Global Recombinant DNA Technology Market
- Market Size Estimates: Global recombinant DNA technology market size estimation in terms of value ($M) shipment.
- Trend and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments.
- Segmentation Analysis: Global recombinant DNA technology market size by various segments, such as product, component, application, and end use in terms of value.
- Regional Analysis: Global recombinant DNA technology market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different product, component, application, end use, and region for the global recombinant DNA technology market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the global recombinant DNA technology market.
- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
Q.1 What are some of the most promising potential, high-growth opportunities for the global recombinant DNA technology market by product (medical (therapeutic agent, human protein, and vaccine) and non-medical (biotech crops, specialty chemicals, and others), component (expression system (mammalian, bacteria, yeast, baculovirus / insects, and others) and cloning vector), application (food & agriculture, health & diseases (humans and animals), environment, and others), end-use (biotechnology and pharmaceutical companies, academic & government research institutes, and others), and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global recombinant DNA technology market?
Q.5 What are the business risks and threats to the global recombinant DNA technology market?
Q.6 What are the emerging trends in this recombinant DNA technology market and the reasons behind them?
Q.7 What are some changing demands of customers in this recombinant DNA technology market?
Q.8 What are the new developments in this recombinant DNA technology market? Which companies are leading these developments?
Q.9 Who are the major players in this recombinant DNA technology market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this recombinant DNA technology market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global recombinant DNA technology market?
Report Scope
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling
Market Segments Product (Medical (Therapeutic Agent, Human Protein, and Vaccine) and Non-Medical (Biotech Crops, Specialty Chemicals, and Others), Component (Expression System (Mammalian, Bacteria, Yeast, Baculovirus / Insects, and Others) and Cloning Vector), Application (Food & Agriculture, Health & Diseases (Humans And Animals), Environment, and Others), and End Use (Biotechnology and Pharmaceutical Companies, Academic & Government Research Institutes, and Others)
Regional Scope North America (USA, Mexico, and Canada), Europe (Germany, United Kingdom, Spain, Italy, and France), Asia (China, Japan, and India), and ROW (Brazil)
Customization 10% Customization without Any Additional Cos
1. EXECUTIVE SUMMARY
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Recombinant DNA Technology Market Trends and Forecast
3.3: Global Recombinant DNA Technology Market by Product
3.3.1: Medical
3.3.1.1: Therapeutic Agent
3.3.1.2: Human Protein
3.3.1.3: Vaccine
3.3.2: Non-Medical
3.3.2.1: Biotech Crops
3.3.2.2: Specialty Chemicals
3.3.2.3: Others
3.4: Global Recombinant DNA Technology Market by Component
3.4.1: Expression System
3.4.1.1: Mammalian
3.4.1.2: Bacteria
3.4.1.3: Yeast
3.4.1.4: Baculovirus / Insects
3.4.1.5: Others
3.4.2: Cloning Vector
3.5: Global Recombinant DNA Technology Market by Application
3.5.1: Food & Agriculture
3.5.2: Health & Diseases
3.5.2.1: Humans
3.5.2.2: Animals
3.5.3: Environment
3.5.4: Others
3.6: Global Recombinant DNA Technology Market by End Use
3.6.1: Biotechnology and Pharmaceutical Companies
3.6.2: Academic & Government Research Institutes
3.6.3: Others
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Recombinant DNA Technology Market by Region
4.2: North American Recombinant DNA Technology Market
4.2.1: Market by Product: Medical (Therapeutic Agent, Human Protein, and Vaccine) and Non-Medical (Biotech Crops, Specialty Chemicals, and Others)
4.2.2: Market by Component: Expression System (Mammalian, Bacteria, Yeast, Baculovirus / Insects, and Others) and Cloning Vectors
4.2.3: Market by Application: Food & Agriculture, Health & Diseases (Humans and Animals), Environment, and Others
4.2.4: Market by End Use: Biotechnology and Pharmaceutical Companies, Academic & Government Research Institutes, and Others
4.2.5: The United States Recombinant DNA Technology Market
4.2.6: The Canadian Recombinant DNA Technology Market
4.2.7: The Mexican Recombinant DNA Technology Market
4.3: European Recombinant DNA Technology Market
4.3.1: Market by Product: Medical (Therapeutic Agent, Human Protein, and Vaccine) and Non-Medical (Biotech Crops, Specialty Chemicals, and Others)
4.3.2: Market by Component: Expression System (Mammalian, Bacteria, Yeast, Baculovirus / Insects, and Others) and Cloning Vector
4.3.3: Market by Application: Food & Agriculture, Health & Diseases (Humans and Animals), Environment, and Others
4.3.4: Market by End Use: Biotechnology and Pharmaceutical Companies, Academic & Government Research Institutes, and Others
4.3.5: The German Recombinant DNA Technology Market
4.3.6: The United Kingdom Recombinant DNA Technology Market
4.3.7: The Spain Recombinant DNA Technology Market
4.3.8: The Italy Recombinant DNA Technology Market
4.3.9: The French Recombinant DNA Technology Market
4.4: APAC Recombinant DNA Technology Market
4.4.1: Market by Product: Medical (Therapeutic Agent, Human Protein, and Vaccine) and Non-Medical (Biotech Crops, Specialty Chemicals, and Others)
4.4.2: Market by Component: Expression System (Mammalian, Bacteria, Yeast, Baculovirus / Insects, and Others) and Cloning Vector
4.4.3: Market by Application: Food & Agriculture, Health & Diseases (Humans and Animals), Environment, and Others
4.4.4: Market by End Use: Biotechnology and Pharmaceutical Companies, Academic & Government Research Institutes, and Others
4.4.5: The Chinese Recombinant DNA Technology Market
4.4.6: The Indian Recombinant DNA Technology Market
4.4.7: The Japanese Recombinant DNA Technology Market
4.5: ROW Recombinant DNA Technology Market
4.5.1: Market by Product: Medical (Therapeutic Agent, Human Protein, and Vaccine) and Non-Medical (Biotech Crops, Specialty Chemicals, and Others)
4.5.2: Market by Component: Expression System (Mammalian, Bacteria, Yeast, Baculovirus / Insect, and Others) and Cloning Vector
4.5.3: Market by Application: Food & Agriculture, Health & Disease (Human and Animal), Environment, and Others
4.5.4: Market by End Use: Biotechnology and Pharmaceutical Companies, Academic & Government Research Institutes, and Others
4.5.5: Brazilian Recombinant DNA Technology Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Product Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Recombinant DNA Technology Market by Product
7.1.2: Growth Opportunities for the Global Recombinant DNA Technology Market by Component
7.1.3: Growth Opportunities for the Global Recombinant DNA Technology Market by Application
7.1.4: Growth Opportunities for the Global Recombinant DNA Technology Market by End Use
7.1.5: Growth Opportunities for the Global Recombinant DNA Technology Market by Region
7.2: Emerging Trends in the Global Recombinant DNA Technology Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Recombinant DNA Technology Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Recombinant DNA Technology Market
7.3.4: Certification and Licensing
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: F. Hoffmann-La Roche Ltd.
8.2: Profacgen
8.3: Amgen Inc
8.4: Company
8.5: Company
8.6: Company
8.7: Company
8.8: Company
8.9: Company
8.10: Company
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Recombinant DNA Technology Market Trends and Forecast
3.3: Global Recombinant DNA Technology Market by Product
3.3.1: Medical
3.3.1.1: Therapeutic Agent
3.3.1.2: Human Protein
3.3.1.3: Vaccine
3.3.2: Non-Medical
3.3.2.1: Biotech Crops
3.3.2.2: Specialty Chemicals
3.3.2.3: Others
3.4: Global Recombinant DNA Technology Market by Component
3.4.1: Expression System
3.4.1.1: Mammalian
3.4.1.2: Bacteria
3.4.1.3: Yeast
3.4.1.4: Baculovirus / Insects
3.4.1.5: Others
3.4.2: Cloning Vector
3.5: Global Recombinant DNA Technology Market by Application
3.5.1: Food & Agriculture
3.5.2: Health & Diseases
3.5.2.1: Humans
3.5.2.2: Animals
3.5.3: Environment
3.5.4: Others
3.6: Global Recombinant DNA Technology Market by End Use
3.6.1: Biotechnology and Pharmaceutical Companies
3.6.2: Academic & Government Research Institutes
3.6.3: Others
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Recombinant DNA Technology Market by Region
4.2: North American Recombinant DNA Technology Market
4.2.1: Market by Product: Medical (Therapeutic Agent, Human Protein, and Vaccine) and Non-Medical (Biotech Crops, Specialty Chemicals, and Others)
4.2.2: Market by Component: Expression System (Mammalian, Bacteria, Yeast, Baculovirus / Insects, and Others) and Cloning Vectors
4.2.3: Market by Application: Food & Agriculture, Health & Diseases (Humans and Animals), Environment, and Others
4.2.4: Market by End Use: Biotechnology and Pharmaceutical Companies, Academic & Government Research Institutes, and Others
4.2.5: The United States Recombinant DNA Technology Market
4.2.6: The Canadian Recombinant DNA Technology Market
4.2.7: The Mexican Recombinant DNA Technology Market
4.3: European Recombinant DNA Technology Market
4.3.1: Market by Product: Medical (Therapeutic Agent, Human Protein, and Vaccine) and Non-Medical (Biotech Crops, Specialty Chemicals, and Others)
4.3.2: Market by Component: Expression System (Mammalian, Bacteria, Yeast, Baculovirus / Insects, and Others) and Cloning Vector
4.3.3: Market by Application: Food & Agriculture, Health & Diseases (Humans and Animals), Environment, and Others
4.3.4: Market by End Use: Biotechnology and Pharmaceutical Companies, Academic & Government Research Institutes, and Others
4.3.5: The German Recombinant DNA Technology Market
4.3.6: The United Kingdom Recombinant DNA Technology Market
4.3.7: The Spain Recombinant DNA Technology Market
4.3.8: The Italy Recombinant DNA Technology Market
4.3.9: The French Recombinant DNA Technology Market
4.4: APAC Recombinant DNA Technology Market
4.4.1: Market by Product: Medical (Therapeutic Agent, Human Protein, and Vaccine) and Non-Medical (Biotech Crops, Specialty Chemicals, and Others)
4.4.2: Market by Component: Expression System (Mammalian, Bacteria, Yeast, Baculovirus / Insects, and Others) and Cloning Vector
4.4.3: Market by Application: Food & Agriculture, Health & Diseases (Humans and Animals), Environment, and Others
4.4.4: Market by End Use: Biotechnology and Pharmaceutical Companies, Academic & Government Research Institutes, and Others
4.4.5: The Chinese Recombinant DNA Technology Market
4.4.6: The Indian Recombinant DNA Technology Market
4.4.7: The Japanese Recombinant DNA Technology Market
4.5: ROW Recombinant DNA Technology Market
4.5.1: Market by Product: Medical (Therapeutic Agent, Human Protein, and Vaccine) and Non-Medical (Biotech Crops, Specialty Chemicals, and Others)
4.5.2: Market by Component: Expression System (Mammalian, Bacteria, Yeast, Baculovirus / Insect, and Others) and Cloning Vector
4.5.3: Market by Application: Food & Agriculture, Health & Disease (Human and Animal), Environment, and Others
4.5.4: Market by End Use: Biotechnology and Pharmaceutical Companies, Academic & Government Research Institutes, and Others
4.5.5: Brazilian Recombinant DNA Technology Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Product Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Recombinant DNA Technology Market by Product
7.1.2: Growth Opportunities for the Global Recombinant DNA Technology Market by Component
7.1.3: Growth Opportunities for the Global Recombinant DNA Technology Market by Application
7.1.4: Growth Opportunities for the Global Recombinant DNA Technology Market by End Use
7.1.5: Growth Opportunities for the Global Recombinant DNA Technology Market by Region
7.2: Emerging Trends in the Global Recombinant DNA Technology Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Recombinant DNA Technology Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Recombinant DNA Technology Market
7.3.4: Certification and Licensing
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: F. Hoffmann-La Roche Ltd.
8.2: Profacgen
8.3: Amgen Inc
8.4: Company
8.5: Company
8.6: Company
8.7: Company
8.8: Company
8.9: Company
8.10: Company
